Novotech wins 2017 Asia Pacific Biotech CRO award

SYDNEY, Jan. 8, 2018 /PRNewswire/ -- Leading Asia Pacific CRO Novotech has won Asia Pacific Biotech CRO Company of The Year award in Frost & Sullivan's 2017 Best Practice Awards.

"Over the past 20 years, Novotech has grown to become the leading contract research organisation (CRO) in Asia Pacific.  Novotech has been very focussed on serving the biotech sector, which has allowed it to develop a unique niche in the global industry," said Frost & Sullivan Transformational Health Associate Director Ms Geeta Dhanoa. "Novotech, has succeeded across a diverse range of markets by having strong local leaders and tailoring its approach to address each country's unique clinical trial conditions. Novotech's flexible, customer-centric approach ensures its clients receive the best value from their investment; positioning the company for sustained growth in the region."

Commenting on Novotech's win, Novotech Chief Executive Officer Dr John Moller said, "It is very satisfying to have won the award for this category. Over the last five years, Novotech has heavily invested in helping international biotech companies access the clinical trial benefits available in the Asia Pacific region."

"Working with a regional CRO makes a lot of sense for biotech clients. We believe regional specialisation results in higher quality feasibilities, stronger local KOL and site relationships, and a more comprehensive understanding of local regulatory changes, ensuring time and money is not wasted. The pace of positive reform in our region is extraordinary with many governments working hard toreduce regulatory hurdles, decrease clinical trial approval timelines, and increase levels of government support," explained Dr Moller.

With 13 offices in 11 countries throughout in the Asia Pacific, Novotech actively works with each country's regulatory authorities and clinical trial centres to improve approval processes and timelines. Novotech is committed in providing our clients with access to the untapped benefits available in the Asia Pacific region.

As the leading Asia Pacific CRO, Novotech continues to grow in the region with the:

• Launch of a site monitoring (SMO) business to support clinical trial activity in South Korea and Taiwan
• Signing of MOUs with leading clinical trial networks in Korea with being negotiated throughout the region
• Assisting sites and regulatory authorities to streamline contracts and processes
• Launch of a central laboratory service in Australia

For more information about the untapped clinical trial benefits available in Australia and Asia,
Download free copies of the Frost & Sullivan white papers:

• 'Asia: Preferred Destination for Clinical Trials'
• 'Australia: Preferred Destination for Early Stage Research'

Or feel free to contact us.

About Novotech- www.novotech-cro.com
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence included running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.

For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0

SOURCE Novotech

Related Links

http://www.novotech-cro.com